NCT04829552已完成不适用
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units: A Multicenter Retrospective Cohort Study in the Beaumont Healthcare System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 704
- 试验地点
- 1
- 主要终点
- Inpatient all-cause mortality
研究概览
简要总结
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years old
- •positive reverse transcription-polymerase chain reaction (rRT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens.
- •Intensive care unit (ICU) patient or Step-down unit (SDU) patient on invasive mechanical ventilation, BiPAP, 100% non-rebreather mask, or high flow oxygen or supplemental oxygen of at least 4 liters per minute nasal cannula.
- •peak d-dimer levels exceeding 1,000 mcg/mL at any time during admission.
排除标准
- •Hospital length of stay less than 5 days.
- •Hemorrhage before ICU/SDU admission.
- •Treatment with an anticoagulant other than low molecular weight heparin or unfractionated heparin.
- •Constant treatment with the same dose of anticoagulant for less than 5 days.
结局指标
主要结局
Inpatient all-cause mortality
时间窗: During hospitalization, up to 6 months
次要结局
- Rates of major bleeding events(During hospitalization, up to 6 months)
- Rates of venous thromboses(During hospitalization, up to 6 months)
- Intensive care unit/Step down unit length of stay(During hospitalization, up to 6 months)
研究者
Faisal Musa, MD
Staff Physician
William Beaumont Hospitals
研究点 (1)
Loading locations...
相似试验
终止
4 期
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)COVID-19NCT04406389Weill Medical College of Cornell University14
已完成
4 期
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19COVID-19Venous ThrombosesArterial ThrombosisNCT04367831Columbia University94
已完成
不适用
Thrombosis and Anticoagulation Therapy in Patients with COVID-19 in Japan StudyCoronavirus disease 2019: COVID-19, severe acute respiratory syndrome coronavirus 2: SARS-CoV-2, ThrombosisJPRN-UMIN000045800Fukushima Daiichi Hospital2,894
尚未招募
不适用
The effect of blood clotting and clot reducing medication in blood drawn from patients undergoing liver or pancreas surgery.liver tranplantation, partial hepatectomy, pancreatectomy, cirrhosis, anticoagulation, procoagulantsNL-OMON28973Kings College Hospital NHS Foundation Trust100
Unknown
不适用
Determination of Residual Anticoagulatory Effects of FondaparinuxAnticoagulant Prophylaxis/TherapyNCT01101256Johann Wolfgang Goethe University Hospital110